Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

OncoAlert and ecancer - ESMO 2021 Day 5

ESMO 2021

17 - 21 Sep 2021

Published: 21 Sep 2021

Views: 762

Rating:

Save

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

Dr Gil Morgan from OncoAlert gives his insights on what to look out for from Day 5 of ESMO 2021.

Dr Morgan mentions results from studies including IMpower010, VOICE and REACH-GORTEC.

You can watch Dr Morgan's previous roundup here.

Follow Dr Morgan on twitter: @OncoAlert

Follow ecancer on twitter: @ecancer

Search and follow #OncoAlertTopTweet to stay up to date.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

The role of multidisciplinary tumour board in managing stage 3 lung cancer

Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland

The role of multidisciplinary tumour board in managing stage 3 lung cancer ( Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland )

Loco-regional management after neoadjuvant chemotherapy

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

More from ecancer